Breaking News

CEVEC, Rznomics Ink License Agreement for CAP Technology

Rznomics will use CEVEC’s cell line technology with its trans-splicing ribozyme technology for manufacturing gene therapies targeting various cancers.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CEVEC Pharmaceuticals GmbH and Rznomics Inc. have signed a clinical and commercial license agreement for the use of CEVEC’s CAP Technology for the manufacture of adenoviruses for gene therapy applications. Rznomics will use CEVEC’s cell line technology in combination with Rznomics’ trans-splicing ribozyme technology for manufacturing gene therapies targeting various cancer indications. Financial details were not disclosed. CEVEC’s CAP cell line is based on an engineered human suspension cell...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters